Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
10 janv. 2022 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
07 déc. 2021 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021
30 nov. 2021 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies
04 nov. 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Join S&P SmallCap 600 Index
26 oct. 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy
14 oct. 2021 08h05 HE
|
Avid Bioservices, Inc
Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market World-Class Viral Vector Development and Manufacturing...
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
07 oct. 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
08 sept. 2021 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter...
Avid Bioservices to Participate at Upcoming Investor Conferences
02 sept. 2021 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021
01 sept. 2021 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...